SDF-1α (CXCL12), a ligand of CXCR4, was significantly increased in 95% of therapy-naïve and metastatic ES patients, and high CXCR4 expression was correlated with reduced survival in ES patients. This evidence concerns the gene CXCL12 and Ewing sarcoma.